Robert J. Kreitman, MD, on Hairy Cell Leukemia: Results From an International Study

2018 ASCO Annual Meeting
Tweet this page

Robert J. Kreitman, MD, of the National Cancer Institute, discusses findings on moxetumomab pasudotox in heavily pretreated patients with relapsed or refractory hairy cell leukemia (Abstract 7004).

Jun

Today In Oncology

Eating a High-Quality Diet Could Decrease Cancer Survivors’ Risk of Death by 65%

Older Patients With Melanoma Fare Better on Anti–PD-1 Immunotherapy Than Younger Patients

Total Neoadjuvant Therapy for Borderline Resectable Pancreatic Adenocarcinoma

ASCO Guideline for Geriatric Oncology: Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy

FDA and EMA Accept Regulatory Submissions for Review of Talazoparib for Patients With Germline BRCA-Mutated Metastatic Breast Cancer

;